Impact of shorter MDR tuberculosis regimen drugs on heart rate variability in MDR tuberculosis patients at tertiary care hospital

Disha S. Patel, Chetankumar R. Acharya


Background: Tuberculosis is major cause of death in India. Analysis of heart rate variability is one of the most popular methods of autonomic nervous system evaluation. Shorter MDR-TB regimen drugs affect both central nervous system as well as peripheral nervous system. Existing research suggests that active pulmonary tuberculosis causes ANS dysfunction. So, by HRV measurement impact of shorter MDR-TB regimen drugs on autonomic dysfunction can be correlated. Aim of the current investigation was to evaluate effect of shorter MDR-TB regimen drugs on cardiac autonomic regulation in MDR-TB patients with respect to heart rate variability as a parameter.

Methods: Fifty newly diagnosed MDR-TB patients of either gender on shorter MDR- TB regimen were enrolled in this study after taking consent. After 20 minutes rest, ECG was taken by “physiopac digital polygraph” software for 5 minutes. Two follow-up HRV assessments were done on 2nd month and 4th or 6th month of treatment. HRV was calculated by root mean square deviation of successive differences between adjacent RR intervals (RMSSD) and low frequency and high frequency ratio.

Results: Repeated measures ANOVA showed no statistically significant difference in HRV parameters between baseline, 2 months and 6 months groups. So, sympathetic and parasympathetic modulation in terms of HRV remains unchanged during treatment of MDR-TB with shorter MDR-TB regimen drugs.

Conclusions: Shorter MDR-TB regimen drugs don’t have any significant impact on HRV in MDR- TB patients, No correlation was observed between HRV and heart rate in MDR-TB patients.


Shorter MDR-TB regimen, Autonomic dysfunction, Heart rate variability, Digital polygraph

Full Text:



Fatisson J, Oswald V, Lalonde F. Influence diagram of physiological and environmental factors affecting heart rate variability: An extended literature overview. Heart Int. 2016;11(1):e32-40.

Zygmunt A, Stanczyk J. Methods of evaluation of autonomic nervous system function. Arch Med Sci. 2010;6(1):11-8.

Raimondi G, Contini S, Maria Legramante J, Bocchino M, Sacco S, Pallante M, et al. Autonomic nervous system dysfunction in the course of active pulmonary tuberculosis. Respir Med. 2007;101(8): 1804-8.

Global tuberculosis report 2017. Available at: Accessed on 20 March 2021.

India TB Report 2019. Available at: https://tbcindia. Accessed on 20 March 2021.

The shorter mdr-tb regimen background, recommendations on the use of the shorter MDR-TB regimen. Available at: Short_MDR_regimen_factsheet.pdf. Accessed on 20 March 2021.

Kass JS, Shandera WX. Nervous system effects of antituberculosis therapy. CNS drugs. 2010;24(8): 655-67.

Mason JW, Moon TE. Moxifloxacin increases heart rate in humans. Antibiotics. 2017;6(1):1-9.

Ream CR. Respiratory and cardiac arrest after intravenous administration of kanamycin with reversal of toxic effects by neostigmine. JAMA J Am Med Assoc. 1963;186(2):191.

Choudhri SH, Harris L, Butany JW, Keystone JS. Clofazimine induced cardiotoxicity: A case report. Lepr Rev. 1995;66(1):63-8.

Koide T, Shiba M, Tanaka K, Muramatsu M, Ishida S, Kondo Y, et al. Severe QT interval prolongation associated with moxifloxacin: a case report. Cases J. 2008;1(1):2-5.

Sessa F, Anna V, Messina G, Cibelli G, Monda V, Marsala G, et al. Heart rate variability as predictive factor for sudden cardiac death. 2018;10(2):166-77.

Kleiger RE, Stein PK, Bigger JT. Heart rate variability: Measurement and clinical utility. Ann Noninvasive Electrocardiol. 2005;10(1):88-101.

Andrew TN. Guidelines Heart rate variability. Standards of measurement, physiological interpre-tation, and clinical use. Eur Soc Cardiol. 1987;59: 256-62.

van den Berg ME, Rijnbeek PR, Niemeijer MN, Hofman A, Herpen G van, Bots ML, et al. Normal values of corrected heart-rate variability in 10-second electrocardiograms for all ages. Front Physiol. 2018; 9:1-9.

Migliori GB, D'Arcy Richardson M, Sotgiu G, Lange C. Multidrug-resistant and extensively drug-resistant tuberculosis in the West. Europe and United States: epidemiology, surveillance, and control. Clin Chest Med. 2009;30(4):637-65.

Marcos Abdo Arbex, Marília de Castro Lima Varella, Hélio Ribeiro de Siqueira FAF de M. Antituberculosis drugs: Drug interactions, adverse effects, and use in special situations. Part 2: Second-line drugs. J Bras Pneumol. 2010;36(5)641-56. 2010; 11(3):641-56.

Ethionamide V. Monitoring & management of common adverse effects of MDR/XDR - TB treatment. 2017;3:6782.

Arbex MA, Varella M de CL, Siqueira HR de, Mello FAF de. Antituberculosis drugs: Drug interactions, adverse effects, and use in special situations. Part 1: First-line drugs. J Bras Pneumol. 2010;36(5):641-56.

Sammito S, Böckelmann I, Med P. Reference Values of heart rate variability reference values for time- and frequency-domain heart rate variability measures. Hear Rhythm. 2016;13(6):1309-16.

Arnold JM, Fitchett DH, Howlett JG, Lonn EM, Tardif JC. Resting heart rate: A modifiable prognostic indicator of cardiovascular risk and outcomes? Can J Cardiol. 2008;24:3-8.